Intensive Cardiac Coronary Unit, Heart and Vessel Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Scand Cardiovasc J. 2012 Dec;46(6):324-9. doi: 10.3109/14017431.2012.702919. Epub 2012 Jul 10.
To assess the impact of microalbuminuria on the development of acute kidney injury and to investigate its prognostic role at long term follow-up in 526 consecutive patients with ST elevation myocardial infarction without previously known diabetes.
Microalbuminuria was measured using immunonephelemetry in the urine collected in the night.
Patients with microalbuminuria were older (p = 0.013). They showed higher values of peak glycemia (p = 0.017), peak Tn I (p < 0.001), NT-pro BNP (p = 0.020), ESR (p = 0.003), CRP (p = 0.020), and leukocyte count (p < 0.001). Lower eGFR was observed in patients with microalbuminuria both on admission and during ICCU stay (p = 0.048 and p = 0.003, respectively). A positive correlation was observed between CRP and microalbuminuria (Spearman's rho 0.114, p = 0.024). The composite end point was observed in 73 patients (18 patients died and 59 patients developed acute kidney injury). At multivariable regression analysis, microalbuminuria was an independent predictor of acute kidney injury. At follow-up [42.6 (25th-75th percentile, 17.5-56.8) months], Kaplan-Meier curve analysis showed that patients with microalbuminuria had a lower survival rate in respect to patients without microalbuminuria. Cox regression analysis documented that microalbuminuria was an independent predictor of long term mortality (HR: 1.089; 97% CI 1.036-1.145; p < 0.001).
In a large series of STEMI patients without previously known diabetes submitted to PCI, microalbuminuria, as a marker of endothelial permeability following higher systemic inflammatory activation and larger infarct lesions, is an independent predictor for the development acute kidney injury. Furthermore, microalbuminuria identifies a subset of patients at higher risk for long term mortality.
评估微量白蛋白尿对 ST 段抬高型心肌梗死(STEMI)患者急性肾损伤(AKI)发展的影响,并探讨其在 526 例无既往已知糖尿病的连续 STEMI 患者中的长期预后价值。
使用免疫比浊法在夜间收集的尿液中测量微量白蛋白尿。
微量白蛋白尿患者年龄较大(p = 0.013)。他们的血糖峰值(p = 0.017)、峰值 Tn I(p < 0.001)、NT-pro BNP(p = 0.020)、红细胞沉降率(ESR)(p = 0.003)、C 反应蛋白(CRP)(p = 0.020)和白细胞计数(p < 0.001)较高。微量白蛋白尿患者入院时和 ICCU 住院期间的估算肾小球滤过率(eGFR)均较低(p = 0.048 和 p = 0.003)。CRP 与微量白蛋白尿之间存在正相关关系(Spearman 相关系数 0.114,p = 0.024)。73 例患者发生复合终点事件(18 例死亡,59 例发生 AKI)。多变量回归分析显示,微量白蛋白尿是 AKI 的独立预测因子。在随访期间[42.6(25 至 75 百分位,17.5 至 56.8)个月],Kaplan-Meier 曲线分析显示微量白蛋白尿患者的生存率低于无微量白蛋白尿患者。Cox 回归分析证实微量白蛋白尿是长期死亡率的独立预测因子(HR:1.089;97%CI 1.036-1.145;p < 0.001)。
在接受 PCI 的无既往已知糖尿病的大型 STEMI 患者系列中,微量白蛋白尿作为全身性炎症激活增加和梗死面积增大后内皮通透性的标志物,是 AKI 发展的独立预测因子。此外,微量白蛋白尿确定了一组具有更高长期死亡率风险的患者。